GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroBo Pharmaceuticals Inc (NAS:NRBO) » Definitions » Net Change in Cash

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Net Change in Cash : $-10.93 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is NeuroBo Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

NeuroBo Pharmaceuticals's Net Change in Cash for the three months ended in Dec. 2023 was $-3.40 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.93 Mil.

NeuroBo Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for NeuroBo Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroBo Pharmaceuticals Net Change in Cash Chart

NeuroBo Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.08 -3.83 6.30 16.98 -10.93

NeuroBo Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.81 -2.55 -2.13 -2.85 -3.40

NeuroBo Pharmaceuticals Net Change in Cash Calculation

NeuroBo Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-10.799+-0.05+-0.08+0
=-10.93

NeuroBo Pharmaceuticals's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.393+-0.009+0+0
=-3.40

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroBo Pharmaceuticals Net Change in Cash Related Terms

Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroBo Pharmaceuticals Inc (NAS:NRBO) » Definitions » Net Change in Cash
Comparable Companies
COCP CNTX QSAM TFFP AXLA LSTA NTRB FRES SYBX KALA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
200 Berkeley Street, Office 19th Floor, Boston, MA, USA, 02116
Website
https://www.neurobopharma.com
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Executives
James Patrick Tursi director 106 ASHLEY COURT, MOORESTOWN NJ 08057
Marshall H Woodworth officer: Acting Chief Financial Officer C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mark A Glickman director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joseph Hooker officer: Interim CEO and President C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
E&healthcare Investment Fund Ii 10 percent owner 16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211
E&investment, Inc. 10 percent owner 16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000
Hyung Heon Kim director C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000
Andrew I Koven director 3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019
Na Yeon Kim director, 10 percent owner C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115
Richard Kang director 9451 SUNNYFIELD COURT, POTOMAC MD 20854
D Gordon Strickland director C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063
Ben Gil Price officer: CEO and President 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Akash Bakshi director, officer: SVP and COO 602 BAINBRIDGE STREET, FOSTER CITY CA 94404